PROPEL offers one of the world’s largest collections of patient-derived xenografts (PDX) for adult and pediatric leukemias. Academic researchers may request PDX samples free of charge under a material transfer agreement and with no obligation to collaborate.
Visit the PROPEL data portal to browse hundreds of available leukemia xenograft samples, submit a request and view associated genetic data for xenografts and primary tumors. Samples have been derived from diverse subtypes of B- and T-lineage acute lymphoblastic leukemia, acute erythroid leukemia, and mixed-phenotype acute leukemia. Additional subtypes and cases of acute leukemia, including acute myeloid leukemia, are continually being established and added to the resource.
Leukemias are a leading cause of cancer-related death in children and adults, despite therapeutic advances that have improved outcomes. Furthermore, long-term side effects of treatment often lead to serious challenges for survivors.
PROPEL is an initiative of St. Jude Children’s Research Hospital that is designed to advance fundamental research on the biology of leukemia and help develop cures by sharing unique xenograft samples with researchers around the world. PROPEL was developed by the St. Jude Comprehensive Cancer Center Hematological Malignancies Program, the co-leaders of which are Charles G. Mullighan, MBBS (Hons), MSc, MD, and Ching-Hon Pui, MD.